Halozyme Therapeutics retained earnings (accumulated deficit) for the quarter ending December 31, 2024 were $0.360B, a 297.43% increase year-over-year.
Halozyme Therapeutics retained earnings (accumulated deficit) for 2024 were $0.36B, a 297.43% increase from 2023.
Halozyme Therapeutics retained earnings (accumulated deficit) for 2023 were $0.091B, a 36.77% decline from 2022.
Halozyme Therapeutics retained earnings (accumulated deficit) for 2022 were $0.143B, a 343.1% decline from 2021.